Axolotl Biologix

Name

Axolotl Biologix

Legal name

Axolotl Biologix

Website

https://axobio.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine - Wound Care Allografts

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

akta.pro secondary industry

Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)

Keywords

• Regenerative medicine
• Human amnion grafts
• Wound care products
• Tissue repair allografts
• Biologic wound healing

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Human Amnion Graft Products: Sale of proprietary human amnion allograft products for wound care and tissue repair. Products are sold to healthcare providers including hospitals, outpatient clinics, and ambulatory surgery centers throughout the United States. Multiple product lines (Axolotl Graft, DualGraft, Ultra variants) available in various sizes to meet diverse clinical needs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Axolotl Biologix develops, processes, and sells human amnion-derived allograft graft products used by healthcare providers for wound care and tissue repair. The portfolio includes Axolotl Graft and Axolotl DualGraft for clinic/outpatient use, and Axolotl Graft Ultra and Axolotl DualGraft Ultra for surgical/acute care settings, available in multiple sizes to meet diverse clinical needs. Products are sold to acute care hospitals, outpatient clinics, physician offices, ambulatory surgery centers (ASCs), and wound care centers across 44 U.S. states.

Product overview

Axolotl Biologix offers a unified portfolio of human amnion graft products for wound care and tissue repair. The portfolio consists of four main products: Axolotl Graft and Axolotl DualGraft for clinic/outpatient use, and Axolotl Graft Ultra and Axolotl DualGraft Ultra for surgical/acute care settings. All products leverage the regenerative properties of human amnion to enhance natural healing, reduce inflammation, and minimize scarring. Products are available in multiple sizes (ranging from 1cm x 1cm to 4cm x 8cm) to accommodate diverse wound types and care settings including hospitals and outpatient clinics.

Differentiator

Problem solved

Functional benefit

Brands

• Axolotl Graft: Clinic product line of human amnion graft for wound care and tissue repair
• Axolotl Graft Ultra
• Axolotl DualGraft
• Axolotl DualGraft Ultra

Products and services

• Axolotl Graft Human amnion graft product for wound care and tissue repair, available in multiple sizes (1cm x 1cm to 4cm x 8cm) for use in clinic and outpatient settings. Designed for healthcare providers treating patients needing regenerative wound healing.
• Axolotl Graft Ultra Advanced surgical human amnion graft product for enhanced wound care and tissue repair with superior handling properties. Aimed at surgical and acute care settings requiring enhanced regenerative performance.
• Axolotl DualGraft Dual-layer human amnion graft product for wound care and tissue repair, providing enhanced structural support and regenerative benefits. Available for both clinic and surgical applications.
• Axolotl DualGraft Ultra Advanced dual-layer surgical human amnion graft product for enhanced wound care with maximum regenerative properties. Targeted at demanding surgical and acute care scenarios.

Quantifiable outcome

• 30,000+ patients treated successfully with amnion graft products
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and supporting.

• OrthoExcoreChannel Partner/ Reseller/ DistributorStrategic partnership with OrthoEx for distribution and market access of amnion graft products to orthopedic and wound care providers.
• Total AncillarycoreChannel Partner/ Reseller/ DistributorPartnership with Total Ancillary for product distribution and market access across healthcare facilities and provider networks.
• HealthTrustcoreChannel Partner/ Reseller/ DistributorStrategic partnership with HealthTrust for distribution and market access to healthcare providers through their purchasing network.
• OrthoBookssupportingChannel Partner/ Reseller/ DistributorPartnership with OrthoBooks for distribution and market access supporting product reach to healthcare providers.
• Serena GroupcoreChannel Partner/ Reseller/ DistributorStrategic partnership with Serena Group for distribution of amnion graft products, particularly in wound care and tissue repair applications.
• Fusion OrthopedicssupportingChannel Partner/ Reseller/ DistributorPartnership with Fusion Orthopedics for product distribution and market access in orthopedic wound care applications.

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• MiMedx: MiMedx is a leading developer and manufacturer of human amnion/chorion membrane allografts (EpiFix, AmnioFix, AmnioCord) for wound care and tissue repair. It is the most direct competitor to Axolotl in the regenerative wound care and orthobiologics category with overlapping products, customers, and distribution channels.
• Organogenesis: Organogenesis is a regenerative medicine company offering advanced wound care products including Apligraf, Dermagraft, and amniotic allografts (e.g., Affinity, NuShield). It competes directly with Axolotl in outpatient wound care clinics, hospitals, and ASCs.
• MTF Biologics: MTF Biologics is a non-profit tissue bank that develops and distributes amnion-based allografts (e.g., AmnioBand) used in wound care and orthopedic applications. It is one of the largest amnion tissue providers in the US, competing head-to-head with Axolotl for the same clinical indications.
• AlloSource: AlloSource is an AATB-accredited non-profit tissue processor producing allografts including amnion products (e.g., AlloWrap) for wound, orthopedic, and sports medicine applications. It competes with Axolotl in the regenerative tissue space with overlapping channel partners.
• LifeNet Health: LifeNet Health is a leading AATB-accredited allograft provider offering amnion and placental tissue products for wound care and orthopedics. It competes with Axolotl in similar hospital, outpatient, and ASC channels with comparable clinical indications.

Broad incumbents

• Integra LifeSciences: Integra LifeSciences is a diversified medical technology company with a strong regenerative tissue technologies portfolio (e.g., Integra Dermal Regeneration Template, amniotic allografts) sold across the same hospital and outpatient channels as Axolotl.
• Smith+Nephew: Smith+Nephew's Advanced Wound Management division (including the Grafix placental membrane allograft) competes with Axolotl's products in chronic wound and tissue repair applications across hospitals and outpatient settings.
• ConvaTec: ConvaTec is a global medical products company with a significant advanced wound care franchise (including InnovaBurn placental allograft) that targets the same chronic wound, diabetic foot ulcer, and post-surgical healing use cases as Axolotl.
• Coloplast: Coloplast's Wound & Skin Care business offers advanced wound dressings and biologics for chronic wounds. It serves similar outpatient wound care centers and home health channels that constitute Axolotl's primary customer base.

Emerging players

• Surgenex: Surgenex is a smaller regenerative medicine company producing amniotic membrane and umbilical cord allografts (e.g., SurGraft, SurFactor) for wound healing and tissue repair. It is comparable to Axolotl as a smaller-scale, focused competitor in the same allograft category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/axolotlbiologix
• Facebookfacebook.com/axobio
• LinkedInlinkedin.com/company/axolotl-biologix

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Axolotl Biologix